MDxHealth (MDXH) Expected to Announce Earnings on Wednesday

Key Points

• MDxHealth is expected to announce its Q2 2025 earnings on August 20th, with analysts predicting a loss of <$0.13 per share and revenue of $26.31 million.
• The company recently reported earnings for the previous quarter, with an EPS of <$0.15, missing the estimate by $0.02, although revenue matched expectations.
• Analysts have varied opinions on MDxHealth, with Wall Street Zen upgrading its rating to "hold" while Craig Hallum initiated coverage with a "buy" rating and an $8.00 price target.

MDxHealth (NASDAQ:MDXH - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 20th. Analysts expect MDxHealth to post earnings of ($0.13) per share and revenue of $26.31 million for the quarter. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 274.67% and a negative net margin of 34.98%. The business had revenue of $26.60 million for the quarter, compared to the consensus estimate of $26.60 million. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MDxHealth Stock Up 0.4%

MDxHealth stock traded up $0.01 during midday trading on Friday, hitting $2.85. 87,150 shares of the company's stock were exchanged, compared to its average volume of 116,008. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.92 and a current ratio of 2.00. MDxHealth has a 12 month low of $1.35 and a 12 month high of $3.50. The firm has a 50-day moving average of $2.33 and a two-hundred day moving average of $1.95. The company has a market cap of $134.78 million, a PE ratio of -3.24 and a beta of 1.41.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, May 24th. Craig Hallum assumed coverage on shares of MDxHealth in a report on Thursday, July 17th. They set a "buy" rating and a $8.00 target price on the stock.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.